"id:ID","studyInvestigationalInterventions","label","documentVersion","studyDesignRationale","uuid","id","description","bcCategories","studyEstimands","name"
"820","[]","","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","73b75e28-2bd8-42c5-830b-766854355839","StudyDesign_1","The main design for the study","[]","[]","Study Design 1"
